Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Glomerulonephritis
•
Acute kidney injury
How do you manage oral prednisone when initiating nefecon in a patient with IgA nephropathy?
Answer from: at Community Practice
Careful tapering of prednisone and transition planning of budesonide.
Sign In
or
Register
to read more
29009
Related Questions
Do you recommend initiating immunosuppression and plasmapheresis in patients with dialysis dependent AKI in the setting of anti-GBM disease who do not have pulmonary involvement?
What are your top takeaways from ASN 2024?
Do you use delayed-release budesonide over prednisone or methylprednisolone for the treatment of IgA nephropathy, considering the available safety and efficacy data?
Under what circumstances would you consider doing a furosemide stress test in the workup of AKI?
How would you approach the treatment for patients with renal-limited ANCA vasculitis who have persistent proteinuria, hematuria, and ANCA titers and have completed a steroid taper and received three doses of rituximab?
How would you approach the treatment of crescentic fibrillary glomerulonephritis?
How do you approach the management of a patient with an ileostomy who has recurrent prerenal AKI episodes that improve with IV fluids but worsen with each attempt to transition to oral fluids alone?
When giving albumin challenge, for acute kidney injury with suspected hepatorenal syndrome, do you administer a single dose daily or split the dose of albumin?
Which clinical characteristics would prompt you to consider an oral factor B inhibitor such as iptacopan in the treatment of IgA nephropathy?
Do you use PTH levels to help differentiate CKD from AKI in patients who are being evaluated for an elevated creatinine level and who lack long term lab data?